Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M199,075Revenue (TTM) $M52,759Net Margin (%)17.5Altman Z-Score3.5
Enterprise Value $M222,170EPS (TTM) $1.4Operating Margin %27.5Piotroski F-Score5
P/E(ttm)22.4Beneish M-Score-2.9Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book10.910-y EBITDA Growth Rate %2.3Quick Ratio0.8Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %1.2Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow18.3y-y EBITDA Growth Rate %1.3ROA % (ttm)12.4Higher Current Ratio y-yN
Dividend Yield %3.5PEG19.2ROE % (ttm)48.2Less Shares Outstanding y-yY
Payout Ratio %77.0Shares Outstanding M6,818ROIC % (ttm)28.2Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-12-31 Reduce-0.01%$27.08 - $30.96
($28.74)
$ 29.202%Reduce -1.19%14,946,458
RHHBYKen Fisher 2016-09-30 Reduce$30.39 - $32.86
($31.56)
$ 29.20-7%Reduce -0.10%15,126,928
RHHBYKen Fisher 2016-06-30 Add0.01%$30.26 - $33.68
($31.82)
$ 29.20-8%Add 1.58%15,142,209
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 29.20-8%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 29.20-13%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 29.20-16%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 29.20-19%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 29.20-14%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 29.20-20%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 29.20-21%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 29.20-2%Add 99.00%1,803,070
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 29.20-14%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.86)
$ 29.20-8%Add 0.28%1,816,868
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.92)
$ 29.20-6%Add 0.90%1,811,804
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 29.20-6%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.62 - $29.3
($27.78)
$ 29.205%Add 634.57%1,795,722
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 29.2019%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 29.2019%Reduce -3.04%120,548
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.5)
$ 29.2030%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.5)
$ 29.2030%Reduce -7.27%286,946
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Blake Insomnia CEO Dreams of Improving Sleep Jan 04 2017 
    Roche's Leukemia Drug Approved for Next Step in Europe Dec 11 2016 
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
    Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
    Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 

    More From Other Websites
    [video]Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock? Jan 23 2017
    Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies Jan 20 2017
    Breakthrough development for Americans with suspected heart attack - Next generation Troponin T test... Jan 19 2017
    Roche's Franz: No Talks With Novartis on Stake Sale Jan 19 2017
    Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
    Roche Gets Priority Review for Immunotherapy Drug Tecentriq Jan 10 2017
    Roche Pharma Chief Sees Continued Pressure on Drug Prices Jan 09 2017
    FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in... Jan 09 2017
    FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in... Jan 09 2017
    Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication Jan 06 2017
    Roche gains FDA Clearance for 18-Minute Anti-Müllerian Hormone Test to Assess Ovarian Reserve Jan 05 2017
    FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal... Jan 05 2017
    FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal... Jan 05 2017
    Roche launches cobas® c 513 analyzer and HbA1c Gen. 3 assay to meet increasing demand for testing... Jan 04 2017
    Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It Dec 30 2016
    Healthcare: What Does a Trump Administration Mean for Healthcare Stocks? Dec 29 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)